Loading
Mesna is given with the chemotherapy ifosfamide (and high-dose cyclophosphamide) to stop its breakdown products from burning the bladder lining and causing bleeding.
Mesna was approved in December 1988 as a prophylactic agent to reduce the incidence of ifosfamide-induced haemorrhagic cystitis, with oral tablets approved in 2002 allowing intravenous-then-oral schedules; it is given with every ifosfamide dose (sarcoma, germ cell, lymphoma regimens such as ICE and VeIP) and with high-dose cyclophosphamide in transplant conditioning. The label notes it does not prevent haematuria from other causes such as thrombocytopenia. Hypersensitivity reactions, including rare severe skin reactions, and false-positive urine ketone tests are the practical issues; nausea and headache are common.
Free thiol excreted in urine that binds and detoxifies acrolein and 4-hydroxy-ifosfamide, the urotoxic metabolites of ifosfamide and cyclophosphamide, in the bladder.
1.Mesna slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| US | 1988 | Prophylaxis of ifosfamide-induced haemorrhagic cystitis (oral tablets 2002) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Mesna" OR ABSTRACT:"Mesna" OR TITLE:"Mesnex" OR ABSTRACT:"Mesnex" OR TITLE:"Uromitexan" OR ABSTRACT:"Uromitexan" OR TITLE:"Sodium 2-mercaptoethanesulfonate" OR ABSTRACT:"Sodium 2-mercaptoethanesulfonate") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mesna, not a curated reading list.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares the tags supportive, generic.
Shares IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers and the tag generic.